AB Science reçoit un avis d’acceptation pour un brevet européen pour le masitinib dans le traitement du cancer de la prostate métastatique hormono-résistant (mCRPC)
June 26, 2023 12:11 ET
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE REÇOIT UN AVIS D'ACCEPTATION POUR UN BREVET EUROPEEN POUR LE MASITINIB DANS LE TRAITEMENT DU CANCER DE LA PROSTATE METASTATIQUE HORMONO-RESISTANT (mCRPC),...
AB Science receives Notice of Allowance for European patent covering masitinib in the treatment of metastatic castrate refractory prostate cancer (mCRPC)
June 26, 2023 12:11 ET
|
AB Science
PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR EUROPEAN PATENT COVERING MASITINIB IN THE TREATMENT OF METASTATIC CASTRATE REFRACTORY PROSTATE CANCER (mCRPC), STRENGTHENING THE COMPANY’S...
Brachytherapy Seeds Market to reach US$ 191.4 million by 2031, growing at a CAGR of 4.1% from 2023-2031: TMR Report
June 23, 2023 08:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, June 23, 2023 (GLOBE NEWSWIRE) -- The global brachytherapy seeds market is estimated to flourish at a CAGR of 4.1% from 2023 to 2031. According to Transparency...
Global Radioligand Therapy Market Report 2023: Increased Awareness of Alpha Radioimmunotherapy and Rise in R&D Activities Drives Growth
June 23, 2023 06:08 ET
|
Research and Markets
Dublin, June 23, 2023 (GLOBE NEWSWIRE) -- The "Radioligand Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027" report has been added to ...
Arvinas Announces Changes to its Board of Directors
June 15, 2023 16:30 ET
|
Arvinas Inc.
NEW HAVEN, Conn., June 15, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Vaccitech Doses First Patient in PCA001, a Prostate Cancer Phase 1/2 Clinical Trial of VTP-850 Immunotherapeutic Candidate in Men with Rising PSA after Definitive Local Therapy
June 12, 2023 07:30 ET
|
Vaccitech plc
OXFORD, United Kingdom, June 12, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) (the Company, we or us), a clinical-stage biopharmaceutical company engaged in the discovery and development of...
Arvinas Announces Interim Data from the ARV-766 Phase 1/2 Dose Escalation and Expansion Trial Showing Promising Signals of Efficacy in Late-line mCRPC, Including in Patients with AR L702H Mutations
June 08, 2023 07:00 ET
|
Arvinas Inc.
– 42% of patients with AR ligand binding domain (LBD) mutations achieved PSA50; in patients with AR L702H mutations, 3 of 5 achieved PSA50 – – ARV-766 was well-tolerated, and activity in a heavily...
Global Radiation Oncology Market Report 2023: Demand for Advanced Cancer Treatment Options Fuels Growth
June 06, 2023 05:28 ET
|
Research and Markets
Dublin, June 06, 2023 (GLOBE NEWSWIRE) -- The "Global Radiation Oncology Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.The global radiation...
Arvinas to Participate in Upcoming Investor Conferences
June 05, 2023 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., June 05, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Hofseth Biocare ASA: ADVANCING THE TREATMENT OF PROSTATE CANCER WITH PUBLICATION OF FTH1 RESEARCH ABSTRACT AHEAD OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) MEETING
May 30, 2023 02:40 ET
|
Hofseth Biocare ASA
HBC is pleased to announce the online publication of its abstract titled “Antiproliferative activity of marine-derived oligopeptides combined with androgen receptor inhibition in preclinical cancer...